Biocon Limited (IN:BIOCON)
:BIOCON
Want to see IN:BIOCON full AI Analyst Report?
BIOCON Stock Chart & Stats
₹364.20
₹0.80(0.22%)
At close: 4:00 PM EST
₹364.20
₹0.80(0.22%)
Day’s Range― - ―
52-Week Range₹313.05 - ₹424.95
Previous CloseN/A
Volume1.20M
Average Volume (3M)208.50K
Market Cap
₹566.20B
Enterprise Value₹613.76B
Total Cash (Recent Filing)₹64.69B
Total Debt (Recent Filing)₹165.35B
Price to Earnings (P/E)91.6
Beta0.98
Next Earnings
May 07, 2026EPS Estimate
1.17Next Dividend Ex-DateN/A
Dividend Yield0.12%
Share Statistics
EPS (TTM)0.95
Shares Outstanding1,620,907,700
10 Day Avg. Volume177,351
30 Day Avg. Volume208,504
Financial Highlights & Ratios
PEG Ratio-38.08
Price to Book (P/B)1.88
Price to Sales (P/S)2.66
P/FCF Ratio23.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹435.00Price Target Upside19.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)8.94
Revenue Forecast (FY)₹201.71B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained revenue growth near 14% indicates expanding product adoption and market penetration across geographies. That trend supports durable cash generation, funds R&D and capacity expansion, and underpins scale economics that can strengthen competitive position over the next several quarters.
Diversified Business ModelMultiple revenue streams—biosimilars/biologics, generics/APIs, CDMO services and licensing—reduce dependence on any single product or market. This structural diversification smooths cyclical swings, supports recurring and milestone income, and aids long-term resilience and strategic optionality.
Positive Cash Flow GenerationImproving operating cash flow and positive free cash flow provide internal funding for capex, R&D and partnership activities without reliance on external financing. Strong cash conversion supports operational autonomy and the ability to sustain investment through multi-quarter development cycles.
Bears Say
Rising Debt ConcernsA noted increase in total debt raises leverage and interest expense risk, which can constrain financial flexibility. If elevated debt persists, it may limit capital allocation to R&D, manufacturing scale-ups or licensing deals and increase vulnerability to higher rates or weaker cash flow periods.
Earnings Per Share DeclineA nearly 28% decline in EPS signals pressure on per-share profitability that may reflect margin compression, one-time items, or higher expenses. Persistent EPS weakness can erode retained earnings and limit the company’s ability to self-fund growth initiatives or deliver improving returns to shareholders.
Erosion Of Operating MarginA falling EBIT margin points to operational headwinds—rising input costs, pricing pressure in biosimilars/generics, or inefficiencies. Sustained margin erosion would reduce free cash flow potential and hinder reinvestment in manufacturing and R&D critical for long-term competitiveness.
Biocon Limited News
BIOCON FAQ
What was Biocon Limited’s price range in the past 12 months?
Biocon Limited lowest stock price was ₹313.05 and its highest was ₹424.95 in the past 12 months.
What is Biocon Limited’s market cap?
Biocon Limited’s market cap is ₹566.20B.
When is Biocon Limited’s upcoming earnings report date?
Biocon Limited’s upcoming earnings report date is May 07, 2026 which is in 9 days.
How were Biocon Limited’s earnings last quarter?
Biocon Limited released its earnings results on Feb 12, 2026. The company reported ₹0.947 earnings per share for the quarter, missing the consensus estimate of ₹1.166 by -₹0.219.
Is Biocon Limited overvalued?
According to Wall Street analysts Biocon Limited’s price is currently Undervalued.
Does Biocon Limited pay dividends?
Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here
What is Biocon Limited’s EPS estimate?
Biocon Limited’s EPS estimate is 1.17.
How many shares outstanding does Biocon Limited have?
Biocon Limited has 1,620,907,700 shares outstanding.
What happened to Biocon Limited’s price movement after its last earnings report?
Biocon Limited reported an EPS of ₹0.947 in its last earnings report, missing expectations of ₹1.166. Following the earnings report the stock price went down -0.146%.
Which hedge fund is a major shareholder of Biocon Limited?
Currently, no hedge funds are holding shares in IN:BIOCON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biocon Limited
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
BIOCON Stock 12 Month Forecast
Average Price Target
₹435.00
▲(19.44% Upside)
Technical Analysis
Blue Jet Healthcare Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―